U.S. Approves Expanded Use of Tryngolza, Moving Treatment for Severe Hypertriglyceridemia Past the Pancreatitis Risk Threshold

For patients with severe hypertriglyceridemia, the concentration of fat in the blood is not just a red mark on a lab report. When triglycerides rise too high, acute pancreatitis can strike suddenly, causing severe pain, hospitalization, and even life-threatening complications. The U.S. Food and Drug Administration (FDA) recently approved a new indication for Ionis Pharmaceuticals’ Tryngolza (olezarsen), to be used together with dietary control to lower triglycerides in adults with severe hypertriglyceridemia and reduce the risk of acute pancreatitis.

The key point of this approval is not simply that there is another triglyceride-lowering drug, but that the FDA said this is the first treatment approved to reduce the risk of acute pancreatitis in this type of patient. According to the drug label, severe hypertriglyceridemia is defined as triglycerides of at least 500 mg/dL. For this indication, Tryngolza is recommended for adults as a 50 mg subcutaneous injection once monthly; if well tolerated and further triglyceride reduction is clinically needed, the dose may be increased to 80 mg once monthly.

Tryngolza’s active ingredient, olezarsen, is an antisense oligonucleotide drug that targets APOC3. APOC3 affects the metabolism of triglyceride-rich lipoproteins; inhibiting its production can, in theory, help lower triglyceride levels in the blood. This type of mechanism extends treatment thinking from traditional lipid regulation to a more specific molecular pathway, but patients still need to combine treatment with dietary management, with clinicians deciding on use based on overall cardiovascular and pancreatitis risk.

The FDA said the approval was based on two randomized, double-blind, placebo-controlled trials that enrolled a total of 1,061 adults. These studies supported Tryngolza’s benefits in lowering triglycerides and reducing the risk of acute pancreatitis. However, the details available in public summaries are limited, and readers should not interpret the approval as meaning that all patients will receive the same degree of protection. Pancreatitis risk is affected by lipid levels, diet, diabetes, alcohol use, medications, and other metabolic conditions, so clinical decisions still need to return to each individual’s condition.

On safety, the label lists more common adverse reactions in the severe hypertriglyceridemia trials, including injection-site reactions and elevated liver enzymes. These signals are reminders that long-term treatment cannot be judged only by lower lipid numbers; tolerability and changes in liver function also need to be monitored. For patients who may already be using multiple lipid-lowering or metabolism-related medications, the overall medication burden also requires attention.

Tryngolza had previously entered the clinical spotlight for rare lipid disorders such as familial chylomicronemia syndrome. The addition of a broader severe hypertriglyceridemia indication means the APOC3 inhibition strategy is gradually moving from rare diseases toward more common high-risk populations. The FDA also granted the application priority review and breakthrough therapy designation, indicating that the regulator believes the treatment may address a medical need that has not been adequately met.

The real test will begin after approval: which patients are most suitable for use, when to increase the dose, how to use it alongside existing lipid-lowering therapies, and whether its effect in reducing pancreatitis events over the long term can be maintained in broader clinical practice. For patients, this approval provides a new treatment option; for the healthcare system, it also pushes the treatment goal for severe hypertriglyceridemia toward more precise risk prevention.